Tech Company Financing Transactions
Brenig Therapeutics Funding Round
On 7/23/2024, Brenig Therapeutics secured $65 million in Series A financing from New Enterprise Associates, BioGeneration Ventures and OrbiMed.
Transaction Overview
Company Name
Announced On
7/23/2024
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
New Enterprise Associates (Lead Investor) (Ed Mathers)
Proceeds Purpose
The company intends to use the funds to advance BT-267 through healthy volunteer studies and into proof-of-concept studies in idiopathic Parkinson's disease patients.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
1209 Orange Street
Wilmington, DE 19801
USA
Wilmington, DE 19801
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Brenig is a small molecule drug development company that utilizes an AI/ML approach via a partnership with Expert Systems Inc., a drug accelerator that has spawned multiple best-in-class clinical candidates across multiple therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Iain Dukes
Browse more venture capital transactions:
Prev: 7/23/2024: Powder venture capital transaction
Next: 7/23/2024: Level AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs